Basit öğe kaydını göster

dc.contributor.authorDikker, Okan
dc.contributor.authorArman, Yucel
dc.contributor.authorUgurlukisi, Bilal
dc.contributor.authorYoldemir, Sengul Aydin
dc.contributor.authorKutlu, Orkide
dc.contributor.authorCil, Eylem Ozgun
dc.contributor.authorKalyon, Semih
dc.contributor.authorOzsoy, Neslihan
dc.contributor.authorOzcan, Mustafa
dc.contributor.authorTukek, Tufan
dc.contributor.authorAkarsu, Murat
dc.contributor.authorAltun, Ozgur
dc.date.accessioned2021-03-02T20:44:59Z
dc.date.available2021-03-02T20:44:59Z
dc.identifier.citationAltun O., Dikker O., Arman Y., Ugurlukisi B., Kutlu O., Cil E. O. , Yoldemir S. A. , Akarsu M., Ozcan M., Kalyon S., et al., "Serum Angiopoietin-like peptide 4 levels in patients with hepatic steatosis", CYTOKINE, cilt.111, ss.496-499, 2018
dc.identifier.issn1043-4666
dc.identifier.othervv_1032021
dc.identifier.otherav_0370822f-b124-4638-92e8-e5a1ebb7a998
dc.identifier.urihttp://hdl.handle.net/20.500.12627/8257
dc.identifier.urihttps://doi.org/10.1016/j.cyto.2018.05.030
dc.description.abstractObjectives: Angiopoietin-like peptide 4 (ANGPTL-4) plays an important role in lipid metabolism by inhibiting the enzyme lipoprotein lipase. This effect of ANGPTL-4 results in suppression of the release of plasma triglyceri-dederived fatty acids. Increase in fatty acid levels entering to the liver and abnormalities in their secretion is one of the main mechanisms in pathogenesis of hepatic steatosis. In this study, we aimed to investigate the role of ANGPTL-4 in pathogenesis of hepatic steatosis by determining its levels in patients with fatty liver disease.
dc.language.isoeng
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectBİYOKİMYA VE MOLEKÜLER BİYOLOJİ
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectHÜCRE BİYOLOJİSİ
dc.subjectİmmünoloji
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectHistoloji-Embriyoloji
dc.subjectYaşam Bilimleri
dc.subjectSitogenetik
dc.subjectTemel Bilimler
dc.titleSerum Angiopoietin-like peptide 4 levels in patients with hepatic steatosis
dc.typeMakale
dc.relation.journalCYTOKINE
dc.contributor.departmentOkmeydam Training & Res Hosp , ,
dc.identifier.volume111
dc.identifier.startpage496
dc.identifier.endpage499
dc.contributor.firstauthorID258408


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster